Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203289 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
A Phase 1 study of Healthy, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT05203289 is a Phase 1 study of Healthy that has completed, run by Boehringer Ingelheim. The registered enrollment target is 200 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05203289, a Phase 1 study of Healthy, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this trial is to compare the pharmacokinetics (PK) of 40 mg BI 695501 100 mg/mL with 40 mg BI 695501 50 mg/mL following single subcutaneous administration.
Conditions Studied
Interventions
- DRUG BI 695501 - higher concentration
- DRUG BI 695501 - lower concentration
Study Locations (2)
Florida
- Miami Research Associates, Inc - Miami
Missouri
- QPS MO - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2022-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05203289
The ClinicalTrials.gov registry entry for NCT05203289 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which BI 695501 - higher concentration is the first listed.
NCT05203289 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT05203289 about?
NCT05203289 is a clinical study titled "A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection". The main objective of this trial is to compare the pharmacokinetics (PK) of 40 mg BI 695501 100 mg/mL with 40 mg BI 695501 50 mg/mL following single subcutaneous administration.
What is the current status of trial NCT05203289?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2022-02-18. Estimated completion is 2022-08-29.
What conditions does trial NCT05203289 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05203289?
The interventions under investigation include: BI 695501 - higher concentration (DRUG), BI 695501 - lower concentration (DRUG).
Who is sponsoring clinical trial NCT05203289?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203289 being conducted?
This trial has 2 study locations across Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.